Literature DB >> 9462524

Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice.

R Elhage1, A Maret, M T Pieraggi, J C Thiers, J F Arnal, F Bayard.   

Abstract

BACKGROUND: The cytokines interleukin 1 (IL-1) and tumor necrosis factor (TNF) are secreted by the different cell populations of the vascular wall and have been suggested to promote atherosclerosis. METHODS AND
RESULTS: Their respective roles in fatty-streak formation in apolipoprotein E-deficient mice were investigated by use of IL-1 receptor antagonist and TNF binding protein. Estradiol-17beta was used as a positive control. Blocking TNF seemed to be active in female animals but not in males. IL-1 receptor antagonist was as effective as or more effective than estradiol in both sexes.
CONCLUSIONS: IL-1 plays a crucial role in the initial step of the atherosclerotic process in this animal model, and blocking the activity of this cytokine should be considered as a therapeutic possibility.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9462524     DOI: 10.1161/01.cir.97.3.242

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  62 in total

1.  Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice.

Authors:  Koichi Kozaki; Wolfgang E Kaminski; Jingjing Tang; Stan Hollenbach; Per Lindahl; Carol Sullivan; Jin-Chen Yu; Keith Abe; Paul J Martin; Russell Ross; Christer Betsholtz; Neill A Giese; Elaine W Raines
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

Review 2.  Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis.

Authors:  Razi Khan; Eric Rheaume; Jean-Claude Tardif
Journal:  Curr Atheroscler Rep       Date:  2018-09-15       Impact factor: 5.113

Review 3.  Inflammasomes and metabolic disorders: old genes in modern diseases.

Authors:  Gregory R Robbins; Haitao Wen; Jenny P-Y Ting
Journal:  Mol Cell       Date:  2014-04-24       Impact factor: 17.970

4.  Pulling down the plug on atherosclerosis: cooling down the inflammasome.

Authors:  Göran K Hansson; Lars Klareskog
Journal:  Nat Med       Date:  2011-07-07       Impact factor: 53.440

5.  Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells.

Authors:  L M Rasmussen; P R Hansen; M T Nabipour; P Olesen; M T Kristiansen; T Ledet
Journal:  Biochem J       Date:  2001-12-01       Impact factor: 3.857

Review 6.  A role for the NLRP3 inflammasome in metabolic diseases--did Warburg miss inflammation?

Authors:  Haitao Wen; Jenny P-Y Ting; Luke A J O'Neill
Journal:  Nat Immunol       Date:  2012-03-19       Impact factor: 25.606

7.  Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice.

Authors:  Matthew R Alexander; Christopher W Moehle; Jason L Johnson; Zhengyu Yang; Jae K Lee; Christopher L Jackson; Gary K Owens
Journal:  J Clin Invest       Date:  2011-12-27       Impact factor: 14.808

Review 8.  Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond.

Authors:  Peter Libby
Journal:  J Am Coll Cardiol       Date:  2017-10-31       Impact factor: 24.094

9.  Suppression of Tie-1 in endothelial cells in vitro induces a change in the genome-wide expression profile reflecting an inflammatory function.

Authors:  Barden Chan; Vikas P Sukhatme
Journal:  FEBS Lett       Date:  2009-02-21       Impact factor: 4.124

10.  High-fat diet induces lung remodeling in ApoE-deficient mice: an association with an increase in circulatory and lung inflammatory factors.

Authors:  Amarjit S Naura; Chetan P Hans; Mourad Zerfaoui; Youssef Errami; Jihang Ju; Hogyoung Kim; Khalid Matrougui; Jong G Kim; A Hamid Boulares
Journal:  Lab Invest       Date:  2009-09-14       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.